Medtronic Enters Exclusive Agreement with Merit for BVNA System
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 24 2026
0mins
Should l Buy MDT?
Source: NASDAQ.COM
- Exclusive Distribution Agreement: Medtronic has signed an exclusive agreement with Merit Medical Systems to launch the FDA-approved ViaVerte system, which is the first BVNA system with a physician-controlled steerable mechanism aimed at treating chronic vertebrogenic lower back pain, significantly enhancing treatment options for patients.
- Product Innovation: The unique design of the ViaVerte system allows physicians to precisely target the basivertebral nerve, thereby improving treatment outcomes and further solidifying Medtronic's leadership in the pain intervention space while providing more effective solutions for chronic pain patients.
- Strengthened Strategic Partnership: This agreement not only expands Medtronic's pain intervention product portfolio but also deepens the ongoing collaboration with Merit, which currently supplies Medtronic with Kyphon Xpander Inflation Syringes and Kyphon KyphoFlex unipedicular steerable balloon catheters used in balloon kyphoplasty procedures.
- Market Impact: By introducing the ViaVerte system, Medtronic enhances its competitiveness in the chronic pain treatment market, which is expected to attract more patients to its innovative treatment options, thereby driving continued growth in the medical technology sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDT
Wall Street analysts forecast MDT stock price to rise
20 Analyst Rating
11 Buy
9 Hold
0 Sell
Moderate Buy
Current: 88.120
Low
102.00
Averages
111.76
High
120.00
Current: 88.120
Low
102.00
Averages
111.76
High
120.00
About MDT
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medtronic to Report Q4 and FY2026 Results on June 3
- Earnings Announcement: Medtronic has announced it will report its fourth quarter and full fiscal year 2026 financial results on June 3, 2026, following the fiscal year ending on April 24, 2026, providing investors with insights into its financial health and performance.
- Global Leadership: As a leader in healthcare technology, Medtronic is committed to addressing significant health challenges, employing over 95,000 people across more than 150 countries, showcasing its extensive influence in the healthcare sector.
- Technology and Treatment Range: The company offers technologies and therapies for 70 health conditions, including cardiac devices, surgical robotics, and insulin pumps, demonstrating its robust capabilities in medical innovation and diverse product offerings.
- Mission and Vision: Medtronic's mission to alleviate pain, restore health, and extend life underscores its commitment to improving global health outcomes, driving people-centered care, and achieving better medical results.
See More
Medtronic to Report Q4 and FY2026 Results on June 3
- Earnings Announcement Schedule: Medtronic is set to report its Q4 and full fiscal year 2026 financial results on June 3, 2026, with the fiscal year ending on April 24, 2026, reflecting the company's commitment to transparency.
- Information Release Timing: Financial information will be released at 5:45 a.m. Central Time, followed by a video webcast, indicating the company's intention to enhance investor confidence through timely communication.
- Commitment to Innovation: Medtronic is dedicated to addressing global health challenges through its innovative technologies and therapies that treat 70 health conditions, underscoring its leadership in the healthcare technology sector.
- Global Team Scale: With over 95,000 employees across more than 150 countries, Medtronic demonstrates its extensive influence and resource integration capabilities in the global healthcare market.
See More
Telix Pharmaceuticals Appoints New Non-Executive Directors
- Board Expansion: Telix Pharmaceuticals announces the appointment of Maria Rivas and William Jellison as Non-Executive Directors effective May 11, 2026, aimed at enhancing governance and financial oversight to support the company's strategic development in the global biopharmaceutical sector.
- Rivas's Background: Maria Rivas brings over 25 years of clinical development and commercialization experience, having served as Chief Medical Officer at Pfizer, where she oversaw the launch of multiple blockbuster medical products, and her expertise is expected to bolster Telix's capabilities in oncology and rare diseases.
- Jellison's Experience: William Jellison has over 30 years of corporate finance leadership experience, including serving as CFO of Stryker Corporation, where he managed international finance and M&A, and his financial acumen will provide critical strategic support for Telix.
- Strategic Implications: This board expansion aligns with Telix's evolution into a global commercial-stage biopharmaceutical company, reflecting the company's commitment to enhancing governance structures and increasing market competitiveness, which is expected to drive long-term growth in the biopharmaceutical industry.
See More
Telix Pharmaceuticals Appoints New Non-Executive Directors
- Board Expansion: Telix Pharmaceuticals announces the appointment of Maria Rivas and William Jellison as Non-Executive Directors effective May 11, 2026, aimed at enhancing governance and financial oversight to support the company's strategic development in the global biopharmaceutical sector.
- Maria Rivas Background: Rivas brings over 25 years of clinical development and commercialization experience, having served as Chief Medical Officer at Pfizer, overseeing the launch of multiple blockbuster drugs, which will provide critical support for Telix's product development and market strategies.
- William Jellison Credentials: Jellison has over 30 years of corporate finance experience in large regulated environments, previously serving as CFO of Stryker, managing international finance and M&A, and his financial management expertise will enhance Telix's capital allocation efficiency.
- Strategic Implications: This board expansion aligns with Telix's evolution as a dual-listed global commercial-stage biopharmaceutical company, reflecting the company's commitment to improving governance structures and market competitiveness, which is expected to drive future business growth.
See More
TELIX ENHANCES BOARD WITH NEW DIRECTOR APPOINTMENTS
New Director Appointments: Telix has strengthened its board by appointing additional directors to enhance governance and strategic oversight.
Focus on Growth: The new appointments are part of Telix's strategy to support its growth initiatives and expand its operational capabilities.
See More
Analysis of High-Yield Stock Investment Opportunities
- Stability of Enterprise Products: Enterprise Products Partners showcases a robust 5.7% dividend yield and a 27-year history of increasing dividends, reflecting its cash flow stability throughout energy cycles; despite market volatility, its fee-based revenue model ensures reliable income.
- Resilience of Realty Income: Realty Income boasts a 5.2% dividend yield and an impressive 31-year dividend growth record, demonstrating its investment strength in the retail sector, maintaining a reasonable 75% FFO payout ratio even through multiple economic downturns, highlighting its strong access to capital markets.
- Growth Potential of Medtronic: While Medtronic's 3.2% dividend yield is lower, its 48-year dividend growth streak and the upcoming spin-off of its diabetes business could enhance profitability; coupled with new product launches, this is expected to drive stock price appreciation.
- Investment Timing in the Market: In the current uncertain market environment, investing in reliable high-yield stocks like Enterprise, Realty Income, and Medtronic could be a strategic move for long-term wealth growth, especially for existing shareholders considering increasing their positions.
See More
Medtronic to Report Q4 and FY2026 Results on June 3
- Earnings Announcement: Medtronic has announced it will report its fourth quarter and full fiscal year 2026 financial results on June 3, 2026, following the fiscal year ending on April 24, 2026, providing investors with insights into its financial health and performance.
- Global Leadership: As a leader in healthcare technology, Medtronic is committed to addressing significant health challenges, employing over 95,000 people across more than 150 countries, showcasing its extensive influence in the healthcare sector.
- Technology and Treatment Range: The company offers technologies and therapies for 70 health conditions, including cardiac devices, surgical robotics, and insulin pumps, demonstrating its robust capabilities in medical innovation and diverse product offerings.
- Mission and Vision: Medtronic's mission to alleviate pain, restore health, and extend life underscores its commitment to improving global health outcomes, driving people-centered care, and achieving better medical results.
See More
Medtronic to Report Q4 and FY2026 Results on June 3
- Earnings Announcement Schedule: Medtronic is set to report its Q4 and full fiscal year 2026 financial results on June 3, 2026, with the fiscal year ending on April 24, 2026, reflecting the company's commitment to transparency.
- Information Release Timing: Financial information will be released at 5:45 a.m. Central Time, followed by a video webcast, indicating the company's intention to enhance investor confidence through timely communication.
- Commitment to Innovation: Medtronic is dedicated to addressing global health challenges through its innovative technologies and therapies that treat 70 health conditions, underscoring its leadership in the healthcare technology sector.
- Global Team Scale: With over 95,000 employees across more than 150 countries, Medtronic demonstrates its extensive influence and resource integration capabilities in the global healthcare market.
See More
Telix Pharmaceuticals Appoints New Non-Executive Directors
- Board Expansion: Telix Pharmaceuticals announces the appointment of Maria Rivas and William Jellison as Non-Executive Directors effective May 11, 2026, aimed at enhancing governance and financial oversight to support the company's strategic development in the global biopharmaceutical sector.
- Rivas's Background: Maria Rivas brings over 25 years of clinical development and commercialization experience, having served as Chief Medical Officer at Pfizer, where she oversaw the launch of multiple blockbuster medical products, and her expertise is expected to bolster Telix's capabilities in oncology and rare diseases.
- Jellison's Experience: William Jellison has over 30 years of corporate finance leadership experience, including serving as CFO of Stryker Corporation, where he managed international finance and M&A, and his financial acumen will provide critical strategic support for Telix.
- Strategic Implications: This board expansion aligns with Telix's evolution into a global commercial-stage biopharmaceutical company, reflecting the company's commitment to enhancing governance structures and increasing market competitiveness, which is expected to drive long-term growth in the biopharmaceutical industry.
See More
Telix Pharmaceuticals Appoints New Non-Executive Directors
- Board Expansion: Telix Pharmaceuticals announces the appointment of Maria Rivas and William Jellison as Non-Executive Directors effective May 11, 2026, aimed at enhancing governance and financial oversight to support the company's strategic development in the global biopharmaceutical sector.
- Maria Rivas Background: Rivas brings over 25 years of clinical development and commercialization experience, having served as Chief Medical Officer at Pfizer, overseeing the launch of multiple blockbuster drugs, which will provide critical support for Telix's product development and market strategies.
- William Jellison Credentials: Jellison has over 30 years of corporate finance experience in large regulated environments, previously serving as CFO of Stryker, managing international finance and M&A, and his financial management expertise will enhance Telix's capital allocation efficiency.
- Strategic Implications: This board expansion aligns with Telix's evolution as a dual-listed global commercial-stage biopharmaceutical company, reflecting the company's commitment to improving governance structures and market competitiveness, which is expected to drive future business growth.
See More
TELIX ENHANCES BOARD WITH NEW DIRECTOR APPOINTMENTS
New Director Appointments: Telix has strengthened its board by appointing additional directors to enhance governance and strategic oversight.
Focus on Growth: The new appointments are part of Telix's strategy to support its growth initiatives and expand its operational capabilities.
See More
Analysis of High-Yield Stock Investment Opportunities
- Stability of Enterprise Products: Enterprise Products Partners showcases a robust 5.7% dividend yield and a 27-year history of increasing dividends, reflecting its cash flow stability throughout energy cycles; despite market volatility, its fee-based revenue model ensures reliable income.
- Resilience of Realty Income: Realty Income boasts a 5.2% dividend yield and an impressive 31-year dividend growth record, demonstrating its investment strength in the retail sector, maintaining a reasonable 75% FFO payout ratio even through multiple economic downturns, highlighting its strong access to capital markets.
- Growth Potential of Medtronic: While Medtronic's 3.2% dividend yield is lower, its 48-year dividend growth streak and the upcoming spin-off of its diabetes business could enhance profitability; coupled with new product launches, this is expected to drive stock price appreciation.
- Investment Timing in the Market: In the current uncertain market environment, investing in reliable high-yield stocks like Enterprise, Realty Income, and Medtronic could be a strategic move for long-term wealth growth, especially for existing shareholders considering increasing their positions.
See More
